NeoGenomics (NASDAQ:NEO) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros, Jr. purchased between $1,001 and $15,000 in NeoGenomics, Inc. stock on May 7th, reflecting his personal investment strategy through his "150 MAIN STREET TRUST" account.
• NeoGenomics shares recently fell 2.9% to $6.42, with a market cap of $826.25 million and mixed financial performance outlined in their latest earnings.
• Several large investors have increased their stakes in NeoGenomics, indicating a growing institutional interest in the company despite its current stock valuation challenges.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of NeoGenomics, Inc. (NASDAQ:NEO). In a filing disclosed on June 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in NeoGenomics stock on May 7th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

NeoGenomics Price Performance

NASDAQ:NEO traded down $1.28 on Tuesday, hitting $5.18. The company had a trading volume of 7,266,924 shares, compared to its average volume of 1,825,368. The stock has a market capitalization of $666.41 million, a price-to-earnings ratio of -8.36 and a beta of 1.63. The company has a current ratio of 2.05, a quick ratio of 1.95 and a debt-to-equity ratio of 0.38. The firm has a 50 day moving average of $7.18 and a two-hundred day moving average of $9.48. NeoGenomics, Inc. has a 52 week low of $4.80 and a 52 week high of $19.11.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The medical research company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.09). NeoGenomics had a negative net margin of 11.54% and a negative return on equity of 2.21%. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Institutional Trading of NeoGenomics

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in NeoGenomics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock worth $234,673,000 after acquiring an additional 195,793 shares during the period. First Light Asset Management LLC increased its holdings in NeoGenomics by 90.8% during the 1st quarter. First Light Asset Management LLC now owns 6,042,822 shares of the medical research company's stock worth $57,346,000 after acquiring an additional 2,875,237 shares during the period. Greenhouse Funds LLLP increased its holdings in NeoGenomics by 5.3% during the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after acquiring an additional 237,491 shares during the period. Dimensional Fund Advisors LP grew its stake in NeoGenomics by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock worth $56,645,000 after buying an additional 78,211 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in NeoGenomics by 14.7% in the 1st quarter. American Century Companies Inc. now owns 3,319,602 shares of the medical research company's stock worth $31,503,000 after buying an additional 426,341 shares in the last quarter. Institutional investors own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

NEO has been the subject of several analyst reports. Leerink Partnrs downgraded shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group decreased their price objective on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Leerink Partners cut shares of NeoGenomics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $25.00 to $9.00 in a research report on Wednesday, April 30th. Morgan Stanley decreased their price objective on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a research report on Thursday, May 1st. Finally, Guggenheim started coverage on shares of NeoGenomics in a research report on Thursday, May 15th. They set a "neutral" rating for the company. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $13.83.

Insiders Place Their Bets

In related news, CEO Anthony P. Zook purchased 18,900 shares of the business's stock in a transaction on Tuesday, May 6th. The stock was acquired at an average price of $7.88 per share, with a total value of $148,932.00. Following the purchase, the chief executive officer directly owned 18,900 shares in the company, valued at approximately $148,932. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jeffrey Scott Sherman acquired 20,000 shares of the business's stock in a transaction dated Friday, May 2nd. The stock was acquired at an average cost of $7.51 per share, with a total value of $150,200.00. Following the purchase, the chief financial officer directly owned 158,494 shares in the company, valued at $1,190,289.94. This represents a 14.44% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 70,600 shares of company stock worth $550,438. 2.40% of the stock is owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.